BIO 2026: hyperscalers at the door, tariffs at the dock, funding off the table.

Context

BIO International Convention 2026 runs Monday, June 22 through Thursday, June 25 at the San Diego Convention Center, and this year's edition lands in a moment that is crowded, expensive, and starving at the same time. Early-stage biotech rounds are tracking toward their worst year since 2021 (S&P Global, March 11). Trump's 100 percent drug import tariff order, signed in April, has the industry still counting exceptions (Fierce Pharma). And weeks before the doors open, AWS launched Amazon Bio Discovery, an agentic application aimed at the lab-in-the-loop drug discovery workflow that biotech leadership in this convention center has spent a decade owning. Pick a hallway, you land on one of those three pressures.

The year's headline: hyperscalers at the door, tariffs at the dock, funding off the table

Amazon Web Services dropped Amazon Bio Discovery in late April, the same window BIO finalized its 130-plus session program. Positioned as the AI engine for drug discovery and explicitly built on the lab-in-the-loop pattern (AWS blog, About Amazon, PYMNTS, all from the same launch cycle), the move escalates the cloud-versus-pharma negotiation that ran in the background of BIO 2024 and 2025 into the floor conversation. Layer in the 100 percent drug import tariffs, CSL's $1.5 billion Illinois plasma facility expansion announced March 9 with Governor Pritzker on stage, and S&P Global's flag that U.S. biotech rounds are at their lowest in five years, and the operator question for the week is no longer 'what is the science.' It is 'who can still fund it, who can manufacture it onshore, and who owns the discovery layer in 2027.' Every plenary, every Premier Sponsor booth, and most of the partnering meetings collapse back to that three-part question.

Speakers and plenaries worth showing up for

BIO has published its program; the official speaker page reveals only partial previews to non-registered visitors, and there is no per-speaker public signal in the bundle to ground individual-name takes. So watch roles, not names.

1. The BIO leadership opening. Whoever delivers the gavel session sets the tariff frame for the week. The honest test: does BIO leadership name Amazon Bio Discovery from the podium, or treat agentic discovery as 'one of several digital transformations'? Naming it signals confrontation; sidestepping it signals partnership.
2. The AWS Health and Life Sciences keynote slot. AWS does not buy a podium slot at BIO without a launch customer. The question worth asking: which Amazon Bio Discovery customer is willing to be named publicly by June 22? If Lilly or Pfizer (both confirmed sponsors) is the answer, the discovery layer is largely decided. If the answer is a mid-cap, the negotiation is still open.
3. The Premier Sponsor pipeline showcases (Daiichi Sankyo, Novartis, Pfizer, Takeda, Johnson & Johnson, Servier Europe). Every Premier Sponsor gets a plenary. The useful question is the same for each: how does your 2027 manufacturing footprint change under a 100 percent import tariff that holds? You will learn more from how much they qualify the answer than from the answer itself.
4. The Invest Puerto Rico session. Premier Sponsorship from a U.S. territory investment promotion agency at a tariff-pivot BIO is not subtle. Listen for the Section 936 echo: Puerto Rico is selling itself as the in-territory production play that escapes the import-tariff math.
5. The patient-advocacy and access track. The Trump-administration FDA reshuffle and the next round of Inflation Reduction Act price negotiations will run through one of these sessions whether they appear in the title or not. Patient-advocacy rooms are where the access conversation lands when industry-affairs sessions are too polite to name it.

Breakouts and panels with signal density

1. European Biotech Act crossover sessions. Jones Day's '100 days on' brief is two weeks old; expect Commission staff or EU industry counterparts on the record about regulatory divergence with the U.S. Small rooms, deep signal.
2. Family-office capital tracks. BioSpace flagged in March that the early-stage funding gap is being patched by federal grants and mission-driven family offices. Find the panel where one of those family offices speaks on the record. They are quietly resetting the dilution math for Series A.
3. Plasma and biologics manufacturing supply-chain breakouts. CSL's Illinois expansion is the bellwether; the contract-manufacturers and equipment vendors on these panels will reveal whether the onshoring response is industry-wide or a CSL-shaped one-off.
4. International partnering forums (Servier Europe, Japanese delegations led by Daiichi Sankyo and Nxera Pharma). Listen for whether term sheets are getting longer (vendor lock-in pressure under tariffs) or shorter (caution). The shift, in either direction, tells you how partners are pricing political risk.
5. Agentic-discovery technical sessions. Any session title that includes 'discovery' or 'lab-in-the-loop' without naming a vendor is where the post-Amazon-Bio-Discovery posture gets debated openly. The vendor-naming sessions are pre-staged; the vendor-agnostic ones are real.

Companies to track at the booths

1. Amazon Web Services (Amazon Bio Discovery). What they say: an agentic application that accelerates AI-driven drug discovery for life sciences leadership. What they are actually selling: cloud-of-record lock-in. The discovery layer is a wedge into a decade-long enterprise contract. If you are a mid-cap, the conversation at the booth is not about features. It is about which competitor of yours signed first.
2. CSL (March 9 expansion). What they say: expanded plasma therapy manufacturing in Illinois. What they are actually doing: pricing tariff insurance into the capex plan, with state-incentive money (Pritzker's office announced alongside) reducing the unhedged exposure. Any operator weighing a 2027 U.S. manufacturing decision should ask CSL's commercial team how the Illinois numbers pencil under a 100 percent imports regime.
3. Invest Puerto Rico (Premier Sponsor). What they say: investment promotion for the territory. What they are actually selling: tariff-arbitrage real estate. Premier Sponsorship dollars from a territory IPA at the BIO that opens months after a 100 percent drug import tariff is not coincidence. If a fully domestic onshoring play is too expensive, the Puerto Rico booth has the math.
4. Eli Lilly (Double Helix sponsor). What they say: pipeline depth and GLP-1 scale-up. What they are actually probing: whether Amazon Bio Discovery (or a Google or Microsoft equivalent) deserves a launch-customer slot in a Lilly-scale discovery program. Lilly does not need AWS; AWS needs Lilly. Watch how Lilly's BD team talks about discovery platforms when the question gets specific.
5. Pivot Bio. What they say: consolidating scientific headquarters and manufacturing in St. Louis (St. Louis Magazine, three weeks ago). What they are actually doing: closing the coastal-California chapter. The Berkeley-to-St-Louis move is the agtech-side version of the broader onshoring response, and a capital-discipline read for any investor watching who follows.

Conversation patterns

Three things that will be debated in the hallways:

1. Is Amazon Bio Discovery a partnership opportunity for mid-cap biotechs, or an existential floor-pulling moment that commoditizes discovery? The honest answer probably depends on whether your discovery moat was algorithmic (gone within 24 months) or wet-lab proprietary (intact, for now).
2. Do 100 percent drug import tariffs survive a Q3 federal-court challenge, or are they the new normal every capex plan has to absorb? The legal odds and the political odds are pointing different directions, and CFOs are tired of waiting for clarity before making 2027 manufacturing calls.
3. Is the family-office capital filling the Series A gap durable patient money or bridge money waiting for the IPO window to reopen? The term sheets tell you more than the headline dollar amounts. Ask anyone taking the money to describe the LP base.

One thing nobody is saying:

Steve Ubl is leaving PhRMA at the end of 2026 (Politico, April 8) after a decade as the brand-name pharma lobby's top advocate, at the exact moment the tariff fight and the Inflation Reduction Act price-negotiation rounds expand. PhRMA and BIO have overlapping membership and adjacent (sometimes competing) lobbying turf. Nobody at BIO 2026 will name the succession question publicly because it is delicate. Every government-affairs lead in the building is privately running the shortlist. The most informative twenty minutes of the week might be the government-affairs side rooms, not any plenary.

The follow-up coda

Four days at the San Diego Convention Center, partnering meetings stacked from breakfast through evening receptions, and a card stack that goes cold the moment your flight pushes from the gate. The 72-hour window after BIO closes is where the warm intros stay warm. By the time the post-show inbox flattens them, the best partnering meetings get filed away as 'we should have followed up.' Met is the iPhone app built for that window. Free, no signup, no scrape of your contacts. Sorts the stack by signal, surfaces who to follow up with first, and keeps the warm window open through Monday.